News
KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 ...
ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...
I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...
2don MSN
Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...
Vertex, Inc. (NASDAQ: VERX) ('Vertex” or the 'Company”), a leading global provider of indirect tax solutions, today announced ...
Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.
The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...
1d
Investor's Business Daily on MSNWhy Vertex Pharma Is Feeling The Pain Despite A Second-Quarter BeatVertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results